Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD1a drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD1a/B2M Heterodimer Protein HEK293 expressed (Native Glycosylation), High purity (>95%), Endotoxin controlled. Sequence Verified. Supports native lipid-antigen presentation conformation. |
View CD1A Products |
| Gene Delivery | CD1a Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for Flow Cytometry validation and CAR-T cytotoxicity assays. |
View CD1A Products |
| Benchmark Ab | Anti-CD1a Recombinant Antibody Recombinant positive control derived from benchmark clinical/diagnostic clones (e.g., NA1/34-HLK). Sequence verified. |
View CD1A Products |
| Validator | CD1a siRNA Set For knockdown verification in dendritic cells or T-ALL cell lines. |
View CD1A Products |
| Related Target A | B2M (Beta-2 Microglobulin) Essential heterodimerization partner required for stable CD1a surface expression and structural integrity. |
View B2M Products |
| Related Target B | CD1d Homologous lipid-presenting molecule. Crucial for off-target and selectivity screening panels. |
View CD1D Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Instability (CD1a requires B2M) | Co-expressed CD1a/B2M heterodimer proteins preserve the native antigen-presenting groove. |
| Cross-reactivity within CD1 family | Selectivity panels including CD1a, CD1b, CD1c, and CD1d recombinant proteins verified by Mass Spectrometry. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and validated siRNA sets included. |
| False Positives in Cell Assays | Lentivirus-driven CD1a stable cell lines offer robust, reproducible surface expression for flow cytometry. |
Live CD1a R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CD1a is gaining significant momentum, transitioning from its traditional role as a diagnostic marker for Langerhans cell histiocytosis (LCH) to a highly specific therapeutic target. The clinical pipeline is primarily split between CAR-T cell therapies for cortical T-cell Acute Lymphoblastic Leukemia (coT-ALL) and monoclonal antibodies designed to block lipid-antigen presentation in autoimmune skin diseases such as psoriasis and atopic dermatitis.
As first-generation CD1a-targeted CAR-T therapies progress through early-phase clinical trials, the focus is shifting toward overcoming the challenge of transient T-cell aplasia (since CD1a is expressed on developing thymocytes) and optimizing lipid-ligand binding modulation to selectively downregulate inflammatory immune responses without systemic immunosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T Therapy | Josep Carreras Leukemia Research Institute, Academic Sponsors | Cortical T-ALL (coT-ALL) | Target cell validation (Need CD1a Lentivirus for stable cell lines to perform cytotoxicity assays) |
| Monoclonal Antibody (Blocking) | Biopharma Consortia, Autoimmune Startups | Psoriasis, Atopic Dermatitis | Lipid-binding competition assays (Need stable CD1a/B2M heterodimer proteins) |
| Bispecific / Engagers | Oncology Biotechs | Langerhans Cell Histiocytosis (LCH) | Heterodimer validation and affinity determination (Need high-purity CD1a ECD-Fc) |